Baird on Lineage Cell Therapeutics Inc. (LCTX): 'Incrementally positive following partner's R&D Day'

Baird analyst Jack Allen reiterated an Outperform rating and $5.00 price target on Lineage Cell Therapeutics Inc. (NYSE: LCTX)

The analyst comments "Incrementally positive following partner's R&D Day. Lineage partner Roche (RHHBY, not covered) held an R&D day yesterday, and we remain encouraged by management's comments/posture surrounding the OpRegen program. Roche included multiple slides on OpRegen, and the SVP of ophthalmology went so far as to state that OpRegen was a "personal favorite" during his prepared remarks. Signals such as these reinforce our belief that Roche remains committed to the program (especially in the context on an ongoing open-label Phase 2 study)."

For an analyst ratings summary and ratings history on Lineage Cell Therapeutics Inc. click here. For more ratings news on Lineage Cell Therapeutics Inc. click here.

Shares of Lineage Cell Therapeutics Inc. closed at $1.62 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• AI/ML Innovations plans $2M private placement on the CSE
• Freedom Broker Upgrades Serve Robotics (SERV) to Buy